N
MRTX

Nuveen’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Nuveen’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-294,396
Closed -$17.3M – 3335
2023
Q4 		$17.3M Buy
294,396
+15,955
+6% +$897K 0.01% 1248
2023
Q3 		$12.1M Buy
278,441
+46,556
+20% +$1.66M ﹤0.01% 1357
2023
Q2 		$8.38M Sell
231,885
-28,524
-11% -$1.18M ﹤0.01% 1626
2023
Q1 		$9.68M Buy
260,409
+23,135
+10% +$1.04M ﹤0.01% 1510
2022
Q4 		$10.8M Buy
237,274
+96,877
+69% +$6.27M ﹤0.01% 1441
2022
Q3 		$9.8M Sell
140,397
-3,447
-2% -$255K ﹤0.01% 1480
2022
Q2 		$9.66M Buy
143,844
+20,636
+17% +$1.31M ﹤0.01% 1533
2022
Q1 		$10.2M Sell
123,208
-18,823
-13% -$1.92M ﹤0.01% 1628
2021
Q4 		$20.8M Sell
142,031
-15,499
-10% -$2.41M 0.01% 1213
2021
Q3 		$27.9M Sell
157,530
-8,142
-5% -$1.31M 0.01% 1041
2021
Q2 		$26.8M Sell
165,672
-49,169
-23% -$7.89M 0.01% 1149
2021
Q1 		$36.8M Buy
214,841
+5,227
+2% +$1.03M 0.01% 905
2020
Q4 		$46M Buy
209,614
+17,351
+9% +$3.75M 0.02% 727
2020
Q3 		$31.9M Buy
192,263
+9,457
+5% +$1.29M 0.01% 789
2020
Q2 		$20.9M Buy
182,806
+6,210
+4% +$602K 0.01% 1018
2020
Q1 		$13.6M Buy
176,596
+53,401
+43% +$4.79M 0.01% 1111
2019
Q4 		$15.9M Sell
123,195
-900
-0.7% -$86.8K 0.01% 1307
2019
Q3 		$9.67M Buy
124,095
+14,222
+13% +$1.33M ﹤0.01% 1596
2019
Q2 		$11.3M Buy
+109,873
New +$8.55M ﹤0.01% 1520

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nuveen's MRTX Position: Q1 2024 in Review

Nuveen sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 294,396 shares — an estimated $17.3M sold.

Nuveen first reported a position in MRTX in Q2 2019 and held it in 19 quarters. The position peaked at $46M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Nuveen reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Nuveen sold 294,396 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $17.3M.
  • Nuveen first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Nuveen's Mirati Therapeutics, Inc. Common Stock position peaked at $46M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Nuveen's 13F filing for Q1 2024, filed 13 May 2024.